[PDF] Top 20 Interação criança-espaço exterior em jardim de infância
Has 10000 "Interação criança-espaço exterior em jardim de infância" found on our website. Below are the top 20 most common "Interação criança-espaço exterior em jardim de infância".
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.
... for nivolumab and ...initial analysis [6]; six patients in the nivo-lumab arm and one patient in the IC arm had a complete response and were alive at last ...three patients were off-study and ... See full document
41
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial†
... and neck squamous cell carcinoma (HNSCC), including cancers of the lip, oral cavity, larynx, and pharynx, represents the seventh most common malignancy worldwide, with >650 000 cases diagnosed in 2012 ...older ... See full document
53
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
... CheckMate 141 evaluated the efficacy, safety, and patient-reported quality of life of nivolumab monotherapy vs standard single agent of investigator’s choice (IC) in patients with R/M SCCHN ... See full document
13
<p>Efficacy of Nivolumab for Head and Neck Cancer Patients with Primary Sites and Histological Subtypes Excluded from the CheckMate-141 Trial</p>
... edged. First, this was a retrospective study with a small number of patients and selection bias may have resulted from physician subjectivity in deciding which patients should receive ...in ... See full document
6
Prognostic impact of KRAS mutant type and MET amplification in metastatic and recurrent gastric cancer patients treated with first-line S-1 plus cisplatin chemotherapy
... of first- line S-1 plus cisplatin (SP) combination chemotherapy in metastatic and recurrent ...150 patients with histopathologically confirmed metastatic and ... See full document
11
Radioiodine therapy for hyperthyroidism
... Although antithyroid drug is usually the first line of therapy, 50% to 80% of patients have a relapse and recurrent hyperthyroidism within 1 year after stopping of antithyro[r] ... See full document
12
<p>Potential of Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer: Evidence to Date</p>
... The human immune system is a tightly regulated, complex network of co-stimulatory and co-inhibitory signals that serve as “ immune checkpoints ” to prevent exaggerated immune response and autoimmunity. T cell activation ... See full document
8
Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress
... agent nivolumab is currently being evaluated in a phase I/II study (CheckMate-040) of ad- vanced HCC patients who have previously failed, have refused, or are intolerant of sorafenib ...0.3, ... See full document
10
Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy)
... of patients still relapses and, in particular in B-ALL, the majority of the relapses are caused by the loss of CD19 on leukemic cells ...CD19-targeted therapy resistance have been described, including ... See full document
24
Topotecan Use for Second Line Treatment in Patients with Recurrent or Metastatic Cervical Cancer at Brazilian National Cancer Institute (INCA)
... of patients accrued in these studies render it impossible to compare results among ...treated patients with cervical cancer albeit at a cost of substantial hematologic toxicity ... See full document
241
Personalized treatment for advanced colorectal cancer: KRAS and beyond
... for patients with KRAS WT tumors receiving ...the first-line setting may be restricted to combination use with infusional ...for Metastatic colorectal cancer to determine Efficacy) ... See full document
109
Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment
... and Therapy is an international, peer-reviewed open access journal focusing on the immunological basis of diseases, potential targets for immune based therapy and treatment protocols employed to improve ... See full document
5
Combination therapy with docetaxel and S 1 as a first line treatment in patients with advanced or recurrent gastric cancer: a retrospective analysis
... gastric cancer ranks second among causes of all cancer-related deaths, with about 700,000 confirmed mortalities annually ...gastric cancer is still the second most frequent cause of ... See full document
337
Early and late outcomes of bevacizumab plus chemotherapy versus chemotherapy alone as a neoadjuvant treatment in HER2-negative nonmetastatic breast cancer: a meta-analysis of randomized controlled trials
... breast and axillary lymph nodes (ypT0/isN0) was determined (Figure 3A and B). In CALGB 40603 sub-1, CALGB 40603 sub-2, CALGB 40603, and Bear et al study, a higher pCR rate in the BEV + CT group was not observed. ... See full document
6
Successful treatment of metastatic colorectal cancer with apatinib: report of two cases and literature review
... massive ascites in Jul 2015. The patient obtained PD on CT scans after the termination of chemotherapy. Trifluridine/ tipiracil (TAS-102) and regorafenib were not approved in China at that time, and there were no ... See full document
6
<p>Contemporary Multidisciplinary Management of Sinonasal Mucosal Melanoma</p>
... An analysis of a large database of 1874 patients with SNMM found that complete surgical resection with negative margins signi fi - cantly improves patient ...to patients with negative surgical ... See full document
12
New modalities of cancer treatment for NSCLC: focus on immunotherapy
... Figure 2 Targeted therapy approaches in NSCLC. Targeted therapies work by inactivating proteins essential for tumor growth and survival. Both eGF receptor tyrosine kinase and ALK can be mutated and overactive in ... See full document
83
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
... unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: 575. Results from the phase Ib KEYNOTE-012 expansion cohort[r] ... See full document
13
Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer
... HNSCC, MET is expressed on epithelial cells and is activated by HGF through a paracrine mechanism. HGF is synthesized by stromal fibroblasts as an inactive pre- cursor, and requires activation to generate responses via ... See full document
20
First-line treatment of metastatic melanoma: role of nivolumab
... Figure 1 (A) APC presents tumor-associated antigens to circulating T cells via MHC complex binding to TCR. However, a co-stimulatory signal, provided upon the binding of CD28/B7 is required for T cell activation. ... See full document
5
Related subjects